ClinicalTrials.gg
TerminatedNCT05073484Updated Oct 15, 2026

Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients

A Phase 1 interventional study of BAT6021 and BAT1308 in Advanced Solid Tumor, sponsored by Bio-Thera Solutions. Terminated at 3 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Bio-Thera Solutions · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
Based on the disclosed global research data on the same target drugs, the company has carefully considered and decided to terminate the project to optimize the existing research pipeline.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
13
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This first-in-human open-label, multi center, dose-escalation and expansion study is designed to evaluate the safety, tolerability, and PK of BAT6021 alone or in combination with BAT1308 (an anti-PD-1 antibody) in participants with locally advanced, recurrent, or metastatic incurable tumors for whom standard therapy does not exist, has proven to be ineffective or intolerable, or is considered inappropriate, or for whom a clinical trial of an investigational agent is a recognized standard of care.

Read the detailed description

Anti-PD-1 and anti-PD-L1 antibodies targeting the immuno-inhibitory PD-1 pathway (thus activating T cells) have achieved clinical success in many types of cancers. However, studies have shown that anti-TIGIT antibodies not only trigger T cells and Natural Killer(NK) cells, but they can also activate T cells to a greater extent than anti-PD-1 antibodies. Therefore, further clinical investigation of anti-TIGIT antibodies such as BAT6021 is warranted.

PD-1 and TIGIT are commonly co-expressed in T cells of the same tumor; thus, combining anti-TIGIT antibodies with PD-1/PD-L1 inhibitors may be a more effective cancer treatment. Indeed, anti-TIGIT antibodies have demonstrated synergy with anti-PD-1/PD-L1 antibodies in preclinical models. In addition, sponsor have shown that single administration of BAT1308 or BAT6021 could not effectively inhibit CT26 tumor growth in PD-1/TIGIT- humanized syngeneic mice; however, the combination treatment resulted in potent anti-tumor activity. Therefore, combined treatment with BAT6021 and an anti-PD-1/PD-L1 antibody like BAT1308 could improve therapeutic outcomes.

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

Bio-Thera Solutions is the lead sponsor of 57 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to give voluntary and understand the study and are willing to follow and complete all the test procedures.
  2. Aged ≥ 18 years.
  3. ≥ 3 months.
  4. performance status ≤ 1.
  5. Histologically/ confirmed, locally advanced unresectable or solid tumors that are to standard therapy, or for whom no standard therapy exists.
  6. Has per v1.1. that was not in a prior radiation or other locally treated area, unless imaging-based progression has been clearly documented following radiation or other local therapy.

Exclusion criteria

Exclusion Criteria:

  1. Females who are pregnant or nursing.
  2. Receiving concurrent anticancer therapy or therapy (including chemotherapy, radiation therapy, surgery, immunotherapy, hormonal therapy, targeted therapy, biologic therapy).
  3. Has remaining AEs > Grade 1 from prior antitumor treatment as per v5.0, with the exception of alopecia.
  4. Participants with primacy central nervous system (CNS) , symptomatic , meningeal or are not allowed. Note: Participants with asymptomatic CNS metastases are eligible if clinically controlled, which is defined as 1) ≥ 4 weeks of stable neurologic function following CNS-directed therapy prior to Screening, 2) no evidence of CNS disease progression as determined by radiographic imaging ≥ 4 weeks prior to Screening, 3) ≥ 2 weeks from discontinuation of anti-seizure and therapies (receiving prednisone ≤ 10mg or equivalent steroid therapies is allowed) prior to Screening.
  5. Had major surgery within 28-days of the Screening Visit. Note: Participants who have undergone a non-major surgical procedure ≥ 28 days prior to Screening must have recovered adequately from the toxicity and/or complications from the intervention before administration of the first dose of study drugs.
  6. History of tissue or organ transplantation.
  7. History of severe infection deemed by the PI or designee within 4 weeks or signs and symptoms of any active infection within 2 weeks prior to the first dose of study drugs.
  8. History of (HIV) infection or history of diseases.
  9. Active or C. Note: Hepatitis B virus (HBV) carriers without active disease (HBV DNA titer \< 1000 copies/mL or 200 IU/mL) or cured (negative HCV RNA test) may be enrolled.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    10 mg of BAT6021

    BAT6021 100mg/vial,10mg Ⅳ infusions

    Drug: BAT6021

  • Experimental
    30 mg of BAT6021

    BAT6021 100mg/vial,30mg Ⅳ infusions

    Drug: BAT6021

  • Experimental
    100 mg of BAT6021

    BAT6021 100mg/vial,100mg Ⅳ infusions

    Drug: BAT6021

  • Experimental
    300 mg of BAT6021

    BAT6021 100mg/vial,300mg Ⅳ infusions

    Drug: BAT6021

  • Experimental
    600 mg of BAT6021

    BAT6021 100mg/vial,600mg Ⅳ infusions

    Drug: BAT6021

  • Experimental
    900 mg of BAT6021

    BAT6021 100mg/vial,900mg Ⅳ infusions

    Drug: BAT6021

  • Experimental
    100mg BAT6021+300mg BAT1308

    BAT6021 100mg/vial,BAT1308 100mg/vial ; BAT6021 100mg+BAT1308 300mg Ⅳ infusions

    Drug: BAT6021 · Drug: BAT1308

  • Experimental
    300mg BAT6021+300mg BAT1308

    BAT6021 100mg/vial,BAT1308 100mg/vial ; BAT6021 300mg+BAT1308 300mg Ⅳ infusions

    Drug: BAT6021 · Drug: BAT1308

  • Experimental
    600mg BAT6021+300mg BAT1308

    BAT6021 100mg/vial,BAT1308 100mg/vial ; BAT6021 600mg+BAT1308 300mg Ⅳ infusions

    Drug: BAT6021 · Drug: BAT1308

Interventions

  • DrugBAT6021

    Ⅳ infusions

    Also known as: Recombinant Humanized Anti-TIGIT Antibody Solution for Injection

  • DrugLiscastobartStudies of LiscastobartLiscastobart pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Ⅳ infusions

    Also known as: Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity(DLT)

    DLT is defined as one of the following as investigator related to study drug: Grade 5 toxicity; Hematologic Toxicity ; ≥ Grade 4 anemia; Grade 4 thrombocytopenia that lasts for ≥ 7 days or Grade 3 thrombocytopenia, if associated with clinically significant bleeding (≥ Grade 2 hemorrhage) or requires transfusion of platelets; Grade 4 neutropenia that lasts for ≥ 7 days, or Grade 3 neutropenia that lasts for ≥ 7 days or with documented infection; Grade 3 or Grade 4 febrile neutropenia of any duration.

    Time frame: A minimum of 21 days after first dose of BAT6021

  2. Serious adverse event(SAE)

    Any SAE that is judged by the PI or designee to be related to the study medication must be reported regardless of the amount of time since the last dose received. Follow-up information collected for any initial report of an SAE must also be reported to the Sponsor (or its designee) within 24 hours of receipt by the PI or designee.

    Time frame: From the time of informed consent to 90 days after the last dose or until the initiation of a new cancer treatment.

Secondary outcomes

  1. Pharmacokinetics (PK)

    Cmax

    Time frame: every cycle until cycle 6 (one cycle equals 3 weeks)

  2. Immunogenicity

    Presence of ADAs / neutralizing antibodies (NAbs).

    Time frame: every cycle until cycle 6 (one cycle equals 3 weeks)

07

Study locations

3 sites
  • Liverpool Hospital
    Liverpool, New South Wales, Australia
  • Macquarie University Hospital
    Sydney, New South Wales, Australia
  • Cabrini Hospital Malvern
    Melbourne, Victoria, Australia
08

References and documents

Individual participant data

Plan to share: No — no plan to share IPD

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Mar 2023, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2021
First posted
Oct 11, 2021
StartActual
Oct 29, 2021
Primary completionActual
Mar 30, 2023
CompletionActual
Mar 30, 2023
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: index terms and site details
1 update, last Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Minor edits only
    + 2 other changes: index terms and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05073484
Responsible party
Sponsor
First posted
Oct 11, 2021
Start date
Oct 29, 2021
Primary completion
Mar 30, 2023
Completion
Mar 30, 2023
Last update
Oct 15, 2026

Study contacts

Abhijit Pal, M.D, Ph.D
principal investigator · Medical Oncologist at cancer Therapy, Liverpool Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion